Sinovac's COVID-19 vaccine gains China approval for emergency use in children, adolescents - (Fidelity via NewsPoints Desk)

  • China has approved emergency use of Sinovac's COVID-19 vaccine in young people aged between three and 17, as reported in Fidelity.

  • When that vaccine will be offered to younger groups depends on health authorities formulating China's inoculation strategies, Chairman Yin Weidong. 

  • Yin said minors have lower priority for vaccination against the coronavirus compared with the elderly, who face higher risk of severe symptoms after infection.

  • Preliminary results from Phase I and II clinical trials showed the vaccine could trigger immune response in three to 17 year-old participants, and most adverse reactions were mild.

  • Meanwhile, Sinopharm, which has two shots using similar technology to Sinovac's product, is also submitting data for clearance in younger groups.

  • A vaccine from CanSino Biologics', adopting a different technique, has entered Phase II testing involving those aged between six and 17.

To read more NewsPoints articles, click here.